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 Medulloblastoma is the most common brain tumor in children, accounting 
for 10-20% of primary central nervous system (CNS) neoplasms and 
approximately 40% of all posterior fossa tumors.  It is a highly invasive 
embryonal neuroepithelial tumor that typically arises in the cerebellar vermis and 
has a tendency to disseminate throughout the CNS early in its course. The 
molecular mechanisms of the disease largely remain uncharacterized, as the 
clinical treatment is still associated with mortality and severe side effects.   The 
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development of a clinically relevant in vivo model is important not only to further 
understand the disease but also to provide a method with which to test novel 
therapeutics.   This study quantified the volumetric growth of a human 
medulloblastoma (VC312) in the athymic nude mouse cerebellum using Gd-
enhanced T1-weighed MRI scans.  Additionally, a medulloblastoma flank tumor 
model was used to explore the in vivo effect of the oral anti-cancer agent that 
inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway.  In the 
orthotopic intracerebellar tumor model, perifosine significantly increased the 
survival of treated mice while qualitatively reducing leptomeningeal 
dissemination.  In the flank model, perifosine effectively suppressed the 
volumetric growth, decreased activation of the AKT pathway and reduced cellular 
proliferation in treated mice.  
  
 
Chapter 1 
Introduction 
 
Brain Tumors 
The brain tumor is for both patients and physicians one of the most 
dramatic forms of human disease.  While primary brain tumors only account for 
2% of cancer deaths, their occurrence is responsible for 7% of years of life lost 
before the age of 70 (Kaye and Laws 1995). An estimated 22,070 new cases of 
primary malignant brain and central nervous system tumors were diagnosed in 
the United States in 2009 (12,010 in males and 10,060 in females). This 
represents approximately 1.5% of all primary malignant cancers diagnosed in the 
United States in 2009 (CBTRUS, 2009). 
A primary brain tumor is an accumulation of abnormal cells that starts 
within the cranial vault.   A brain tumor can arise from the tissue of the brain, 
around the brain, nerves, or glands.   Tumors can destroy normal brain cells via 
inflammatory response, causing increased intracranial pressure, or by direct cell-
to-cell contact (Buckner et al., 2007).   Brain tumors are classified by where they 
appear in the Central Nervous System (CNS), which includes the brain and spinal 
cord, the kind of tissue that is involved, the cellular aggressiveness or grade, and 
malignancy (Buckner at el 2007).   The WHO classification is a common 
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neoplasm scaling system that was ratified in 1993 to classify each tumor based 
on its cell of origin (Kleihues et al 1993). 
The difference between normal and neoplastic growth occurs with the 
disruption of several crucial elements of central nervous system (CNS) 
development.  First, normal cell processes such as modulation of cell 
proliferation, differentiation and cell death are altered.  Second, the alteration of 
the microenvironment in and around the cell changes important regulatory cues. 
Thirdly, the combination of these alterations generates a new combination of 
signals that have an effect on the cells intrinsic biologic activity, leading to the 
abnormal growth (Kaye and Laws 1995). 
The most common malignant brain tumor in children is the 
medulloblastoma (MB) (CBTRUS, 2009), a highly invasive embryonal 
neuroepithelial tumor that arises in the cerebellum and tends to disseminate 
throughout the CNS early in its course (MacDonald, 2010). Unfortunately, one-
third of MB tumors remain incurable - while multimodality treatment has 
improved survival, these interventions nevertheless have several damaging 
effects in the long run.  Novel therapies include small molecule inhibitors such as 
perifosine, which has proven effective in peripheral cancers.  Improved tumor 
classification will help improve directed treatment.   An improved model of the 
tumor will include assessment of molecular profiles of the MB and estimated 
growth rates (Gilbertson et al., 2008). 
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Medulloblastoma 
 
Epidemiology: Infratentorial Primitive Neuroectodermal Tumor 
The classification of Primitive Neuroectodermal Tumor or PNET was 
proposed in 1973 by Hart and Earle.  While this distinction was useful in 
developing clinical protocols to treat a range of CNS embryonal tumors, 
especially in children, medulloblastomas demonstrate a confounding diversity, 
unlike other PNETs.  For example, the architectural and cytological features of 
the nodular versus desmoplastic medulloblastoma histologic subtypes are unique. 
The MB’s separation from other PNETs has evolved across editions of the WHO 
(World Health Organization) classification of CNS tumors (1993, 2000, 2007) and 
reflects the MB origin and nature.  The MB is now recognized as a distinctive 
tumor defined by its morphologic and genetic attributes (Gilbertson et al, 2008).   
Recent genetic data out of the Arthur and Sonia Labatt Brain Tumour Research 
Centre, Toronto, Ontario, Canada further enforces this idea by dividing the tumor 
into four distinct molecular subtypes (Northcott et al., 2010). 
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By definition the MB arises in the posterior fossa, specifically in the 
cerebellum (Rorke et al., 1983).  It develops in the vermis and often invades and 
occupies the fourth ventricle; further invasion can involve the brain stem 
(Halperin et al., 2005).   MB accounts for 13% of childhood primary brain and 
CNS tumors (CBTRUS 2010), accounting for approximately 540 diagnosed cases 
a year in the US.  The peak age of incidence is 7 years and the tumor is more 
often seen in boys than girls.   The WHO classifies the medulloblastoma as one 
of five embryonal tumors due to its primitive cellular structure, and grade IV 
because of its aggressive tendency to metastasize (Kleihues et al., 1993).  
Approximately 30% of pediatric patients present with cerebrospinal fluid (CSF) 
metastasis (Fouladi et al., 1999). 
 
Clinical and Laboratory Findings 
Symptoms 
Medulloblastoma patients most commonly present with a three-month 
history of headaches, morning vomiting and lethargy.  Due to the tumor’s classic 
location in the fourth ventricle, patients may experience clumsiness and problems 
with simple tasks.   These initial symptoms are secondary to increased 
Intracranial Pressure (ICP).  Initial signs of ICP are subtle and difficult to 
diagnose.  School age children often show decreased academic performance and 
personality changes. 
! "!
As the tumor increases in size and begins invading the surrounding 
cerebellum, the characteristic symptoms appear.  A particularly common 
symptom is progressively worsening ataxia mainly in the lower extremities (T. 
MacDonald et al., 2009).  For infants, the symptoms are more difficult to 
diagnose.   Mainly, infants demonstrate  difficulty  in  gazing upward and appear 
to have a forced downward eye deviation, the “setting-sun sign” (R.J. Packer et 
al., 1999).   
While MB typically disseminates early in the course of the disease, symptoms of 
the metastases are not characteristic to patient presentation!(Halperin EC et al., 
(2005).   
Diagnosis 
Most  patients with medulloblastoma are diagnosed with a CT scan or 
MRI.  The tumor will appear as a “solid, homogeneous, isodense to hyperdense, 
contrast-enhancing, midline cerebellar mass” (Zimmerman et al., 1978).   The 
MRI is useful for determining the anatomic origin, extent of the disease and 
ruling out cerebellar astrocytoma and ependymoma, which appear similar on the 
CT scan (MacDonald et al., 2009).   
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Figure 1-1. T1-weighted, Contrast-enhanced MRI of a 4-year-old with 
medulloblastoma.  Note the enhanced mass within the fourth ventricle. Image 
taken from Polkinghorn, Figure 1 (2007). 
! "!
 
! "!
Pathology 
Found in the cerebellum, the MB is typically a highly cellular, soft, friable 
tumor composed of cells with deeply basophilic nuclei of variable size and shape, 
sparsely discernible cytoplasm, and abundant mitoses. With the desmoplastic 
subtype, the tumors appear lobulated, sharply demarcated and firm, due to 
reticulin and collagen deposition, when excised surgically (Rosai et al. 2004). 
MBs show a strong tendency to disseminate through the cerebrospinal pathways 
and form tumors of variable size along ventricular surfaces, in the subarachnoid 
space, or along nerve roots.   They have been found to grow “en plaque” 
adjacent to brain or spinal cord (R. Packer et al. 1999).   In various cases, 
Homer-Wright Rosettes, which are ring-like accumulations of tumor cell nuclei 
around a neuropil-containing or fibrillary core, are present.   Varying levels of 
neuronal and glial differentiation are present, suggesting the cell of origin has 
the potential for multiple states of differentiation (T. MacDonald et al. 2009). 
 
Molecular biology/ Pathogenesis of Medulloblastomas 
Medulloblastoma typically arises in the vermis of the cerebellum during 
stages of cerebellar development. The cerebellum is the site of a greater density 
of neurons than the cortex and involves complex signaling pathways during 
development. A common source of medulloblastoma development is an aberrant 
signal from the Sonic Hedgehog (Shh) or Wingless (Wnt) pathway.  These 
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signaling molecules are glycoproteins that are secreted from the Purkinje cell 
layer (PCL) of the cerebellum during cerebellar evolution.  In normal 
development, the Shh or Wnt signal from the Purkinje cells communicates with 
the granule cells in the external granular layer (EGL) to differentiate and migrate 
through the PCL to the internal granular layer (IGL) where they form neurons.  It 
has been proposed that medulloblastoma develops when there is an aberrant 
Shh or Wnt signal from the Purkinie cells, causing the granule cells to divide 
uncontrollably without proper differentiation and migration.    Medulloblastoma is 
interesting because the mutations cause variable tumor histology with tumor 
cells that range from completely undifferentiated to extensively nodulated and 
advanced neuronal differentiation (Fan et al., 2008).  
 
Histology 
The medulloblastoma can divided into four different subtypes based on it’s 
histology; Classic, Desmoplastic, Anaplastic and Extensive Nodularity.  The classic 
MB is believed to be Wnt pathway derived and comprises 65% of all diagnoses.   
The classic histology shows densely packed cells with hyperchromatic nuclei and 
the cells appear to be mostly undifferentiated (Polkinghorn et al. 2007).   
Apoptosis is frequent, whereas areas of necrosis are less common (Kleihues et 
al. 1997). 
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The desmoplastic subtype is associated with a mutated patched-1 
(PTCH1) gene and overactive Shh, making up 25% of all MBs (Polkinghorn et al. 
2007).  The histology shows characteristic pale islands with abundant reticulin 
and collagen, reduced cellularity, rarefied fibrillar matrix and increased apoptosis 
(Rosai et al. 2004). 
The anaplastic or large cell MB shows large, round nuclei with prominent 
nucleoli and large areas of necrosis.  This subtype shows considerable cytologic 
overlap and appears to constitute a unified entity.   Usually high mitotic rates, 
typically abundant apoptotic cellular remains may form “confluent lakes and 
serpiginous seams” (Rosai et al. 2004).   It has been shown that the anaplastic 
subtype incorporates multiple or an accumulation of mutations, with an 
association with decreased survival; it makes up only 5% of MBs (Brown HG et 
al. 2000). 
The extensive nodularity subtype (MBEN) appears to be a variation of the 
desmoplastic subtype with extensive nodularity and advanced neuronal 
differentiation. This subtype is typified by the linear streaming of rounded, 
neuron cell bodies, and tumor cell nuclei within amassed cytoplasmic processes 
(Rosai et al 2004). Defined by the WHO as MB with “intranodular nuclear 
uniformity on a desmoplastic background” (Giangaspero et al., 2007)., this  
subtype is found mostly in infants, is associated with a good prognosis and 
makes up 5% of all MBs (Giangaspero F et al., 1999). 
! ""!
Figure 1-2. Histologic Subtypes of Medulloblastoma. Classic MB with densely 
packed, hyperchromatic nuclei.  Cells appear to be undifferentiated (A), 
Desmoplastic MB with abundant reticulin and collagen (B), Anaplastic / Large Cell 
(LCA) MB with large, round nuclei, prominent nucleoli and large areas of 
necrosis(C), and Extensive Nodularity MB with extensive nodules and advanced 
neuronal differentiation (D).  Images taken from Rosai: Surgical Pathology 9th 
Edition (2004). 
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Molecular Subtypes 
 
Recent studies performed by Paul Northcott and colleagues at the 
University of Toronto Hospital for Sick Children indicate that medulloblastoma 
has four distinct molecular subtypes.   Using Affymetrix and SNP genotyping 
arrays they identified the following subtypes: WNT, SHH, Group C and Group D.   
Each subgroup had a ‘signature’ gene that was over-expressed that was 
identified by commercial antibodies.  The genes and their associated subgroup 
are: DKK1 (WNT), SFRP1 (SHH), NPR3 (Group C) and KCNA1 (Group D) 
(Northcott et al. 2010). 
Treatment  
The current treatment regimen includes surgery, aggressive 
chemotherapy, and relatively high doses of craniospinal radiation therapy. 
Despite these therapies, 5-year survival is at best 60% to 80%, and moreover, 
these therapies affect the developing central nervous system causing memory-, 
attention-, motor function-, language-, and visuospatial deficits (Ribi et al. 2005).    
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Models of Medulloblastoma 
Clinically relevant animal models are needed for the understanding of 
tumor biology and testing novel therapies in medulloblastoma.  The literature 
documents many experimental models of MBs, as described below.  
In vitro 
 In vitro studies are commonplace in research laboratories and allow for 
exploration of tumor cell invasiveness and its causative mechanisms.   Ranger et 
al, used five distinct MB cell lines in 3-D collagen gel assay to assess tumor 
aggressiveness in vitro.   While the three dimensional analysis of the MB cell lines 
effectively maintains the complex relationships between tumor cells in a 3-D 
environment, the model lacks the unique in vivo interactions of the CNS.   
Transgenic Mice 
 Current models of MB transgenic mice have problems with failure to 
generate high tumor incidence and variable latency.   A current model developed 
by Hatton, Villavicencio, Tsuchiya et al.(2008), involves the production of a 
Smo/Smo homozygous mouse, in which a constitutively active form of the 
Smoothened gene is expressed under a granule neuron precursor (GNP)-specific 
promoter.  This medulloblastoma model shows increased tumor incidence, 
predictable tumor latency and displayed a leptomeningeal dissemination of MB 
cells to the brain and spine.  The model appears to recreate the highly 
aggressive and invasive nature of the human disease.   GNPs normally undergo 
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massive expansion during CNS development and their proliferation is regulated 
by the Shh and Notch signaling pathways. The Shh binds to the PTCH receptor 
on GNPs and derepresses the Smoothened receptor, which activates the Shh 
target transcription.  The results of this mouse model producing tumors with 
multiple features of clinically encountered medulloblastoma suggests that 
mutations of this pathway are implicated in the formation of medulloblastoma 
(Hatton, Villavicencio, Tsuchiya et al. 2008).   While the transgenic model is a 
valuable tool for research, it does not incorporate the various types of mutations 
found in human MB tumors.  Further, creating transgenic mice is expensive, is 
not easily reproducible and does not use human tumor-derived cultured cells.  
Therefore, the study of human tumors is impossible with this model. 
Knock Out Mice 
 In knock out mice, an endogenous gene is replaced with a gene that does 
not function correctly.  The mouse is said to be homozygous or heterozygous 
defective depending on whether both or one, respectively, of the homolog genes 
are defective.  This method of engineering mice can be faulty if the target gene 
plays a role in development.  This causes the mice to die before birth or shortly 
thereafter, which is ineffective for research.   A technique for generating 
conditional knockouts has been created to alleviate this problem by turning off a 
particular gene after it has played its role in embryogenesis.   The use of 
genetically engineered mice are valuable to researchers because they allow the 
discovery of which cell signaling pathways play a role in the formation of MB.   
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While the signaling pathways activated in a mouse tumor can be similar to those 
activated in the human disease, there will be distinct differences between the 
human and mouse MB.  Therefore, a mouse model of human tumor-derived cells 
is still necessary.    
Flank Tumor Model 
While the cerebellum is the “true” environment of the MB, a flank tumor 
model has a faster course, is more easily observable, and more tightly controlled 
regarding tumorigenicity and growth parameters.  Subcutaneous flank 
inoculation of athymic nude mice was chosen for this study in addition to 
orthotopic implantation in the cerebellum (see below), because it models a non 
permissive growth environment in which tumor cells must appropriately sense 
and respond to their surroundings to maintain viability, and provides an efficient 
manner of direct tumor growth observation (Pullen, 2010).   Therefore, the effect 
of therapeutic treatment could be compared against it’s effect in mice following 
intra-cerebellar  implantation of tumor cells. 
Orthotopic Model of Medulloblastoma in Mouse Cerebellum 
The orthotopic tumor models present an amount of complexity superior to 
classical pathological models. The implantation of tumor cells in their original 
tissue allows development of tumor comparable to human tumor with production 
of metastasis and interaction of tumor cells with surrounding tissue.   This in situ 
model can provide a reproducible, reliable and objective method of studying the 
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effects of therapeutics.   Xiumei Zhao recently established that orthotopic 
xenograft mouse models of MB replicated the key histopathological phenotypes 
and invasive growth characteristics of the original patient tumors.   This group 
showed that serially passed MB cell lines maintain molecular characteristics for at 
least three generations, thereby proving that xenograft tumors are molecularly 
accurate (Zhao et al. 2010). This further demonstrates the necessity of 
developing a clinically relevant model of the medulloblastoma to examine new 
therapies that can decrease debilitating therapeutic side effects and treatment 
failures that plague patients of MB.   
We designed experiments using this information with the intent of 
creating a molecularly accurate, human tumor-derived medulloblastoma model, 
studying the growth of the disease in the cerebellum, and defining a growth 
curve for MB to enable evaluation of potential new therapeutics for treatment of 
the disease.    
Therapeutics 
Perifosine 
 AKT, also known as Protein Kinase B, is a regulator of cellular survival 
pathways aberrantly active in many human cancers including MB, contributing to 
cellular growth, proliferation and survival (Gills and Dennis, 2009).  These 
characteristics also make AKT an attractive target in cancer therapy and many 
inhibitors of AKT are being developed. Perifosine is an oral AKT inhibitor 
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currently being tested in phase 2 clinical trials in peripheral cancers. It is an 
alkyl-phospholipid, small molecule inhibitor that acts as a competitive inhibitor of 
AKT-kinases. The in vitro effects of the drug have been studied extensively in our 
lab by Anil Kumar (Kumar et al., 2009).  It was found that Perifosine treatment in 
vitro led to the rapid induction of cell death in MB cell lines, with marked 
suppression of phosphorylated AKT in time- and concentration-dependent 
manners (Kumar et al. 2009).  The in vitro studies performed in our lab in 
combination with the proven effectiveness of perifosine in peripheral cancers 
made it an ideal candidate for this study. 
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Chapter 2 
 
Hypothesis and Specific Aims 
Rationale: Thorough examination of many models of medulloblastoma has not 
shown that an existing model can easily reproduce a human tumor-derived 
othrotopic model of the disease.  Tumor volumes provide an objective method of 
studying the tumor growth and effects of therapeutic agents.  The debilitating 
side effects and treatment failures demand new/improved therapies.   We 
attempted to create a medulloblastoma model in the nude mouse cerebellum 
that mimics the molecular fidelity, subtype and histology of the human derived 
tumor.  Further, we compared this model to Perifosine-treated mice. 
 
Hypothesis I: Human cultured medulloblastoma tumor cells can be induced to 
grow in the cerebellum of athymic nude mice to create an orthotopic model. 
 Specific Aims:  
1. Establish effective delivery and placement of tumor inoculum 
into the cerebellum. 
2. Establish a xenograft tumor line with a highly reproducible 
growth pattern in vivo. 
3. Determine the histologic and molecular subtype of 
medulloblastoma grown in the cerebellum. 
! "#!
Hypothesis II: Tumor volume can be measured accurately using MRI to 
determine the volumetric growth of the medulloblastoma. 
 Specific Aims: 
1. Objectively determine the volume of the tumor from MRI scan 
data. 
2. Determination of in vivo growth pattern of primary 
medulloblastoma in mouse cerebellum. 
Hypothesis III: Orthotopic model can be used to demonstrate the effectiveness 
of therapeutics in an in situ model. 
 Specific Aim: 
1. Validate the effective suppression of target signaling molecules 
and volumetric growth in vivo after Perifosine treatment. 
!
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Chapter 3 
Methods 
  
All animal experiments were approved by the Committee for the Care and 
Use of Laboratory Animals at Virginia Commonwealth University.  Female 
athymic nude Fox n1 mice (Harlan, Indianapolis, Indiana) with an average 
weight of 18 to 22 grams were used for all infusions of medulloblastoma cells.  
Stereotactic Infusion 
Female athymic nude mice were anesthetized by inhalation administration of 0.3 
µL/min isoflurane and maintained in an anesthetized state with 0.2 µL/min 
isoflurane during the surgery.   Lubricating veterinary ointment was applied to 
the eyes and the animal was placed on a heating pad in a stereotactic frame.  A 
1 cm midline incision was made at the scalp, centered approximately at lambda.   
An infusion burr hole was stereotactically created 1.5 mm posterior, 3.0 mm 
lateral to lambda using a fine drill bit for all infusions.   A 22s-gauge neede 
attached to a 25 µL Hamilton syringe driven by a syringe pump (Bioanalytical 
Systems, West Lafayette, Indiana) was lowered 3.5 mm below the surface of the 
skull for cerebellar infusions and remained in the cerebellum parenchyma for 5 
minutes before the infusion.   Five minutes after the infusion, the infusion needle 
was slowly raised 1 mm every minute until out of the cerebellum.  The burr holes 
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were sealed with sterile bone wax.   The incision was then closed with Surgi-lock 
2oc (Meridian Animal Health, Omaha, Nebraska), averaging 2 drops along the 
length of the incision and held together for 20 seconds.  The mouse was placed 
under a heat source and monitored until alert and mobile.    Mice had access to 
water containing acetaminophen (1.6mg/mL) (McNeill-PPC, Inc, Fort 
Washington, PA) for three days following initial dose of buprenorphine (0.05-
.1mg/kg, S.C.) immediately following tumor cell infusions for pain alleviation 
during anesthetic recovery.   The recovery method is important due to the 
severely impaired immune systems of these mice. 
 Six µL of 60,000-cells/ µL in plain DMEM (Invitrogen, Carlsbad, CA) was 
infused into the right cerebellum at a flow rate of 0.25 µL/min for 24 minutes.  
Cell implants were permitted to grow for 1 week before MRI scanning to confirm 
tumor formation.  Tumor growth was assessed again at 14 and 21 days via MRI 
T1-weighted imaging, DWI and water mapping techniques.  Twenty-one days 
post-implantation was chosen as a humane endpoint to reduce prolongation of 
potential distress in the animals, since it is a time-point prior to when subject 
mortality would be expected (28-30 days).  Animals were monitored daily for 
signs of pain and distress and if discovered, the animals were euthanized.   
Cerebella were collected and sent to the Department of Anatomic Pathology at 
Virginia Commonwealth University, Richmond, Virginia.  Cerebellum gross 
sections containing intact tumor were then sectioned and subjected to 
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neuropathological analysis to determine volume of tumor and extent of tumor 
cell infiltration of normal cerebellar tissue. 
Subcutaneous Flank Tumor Inoculation 
Animals receiving flank inoculations were not anesthetized.  Cell suspensions 
were prepared in culture medium free of additives.  Target area for inoculation 
was the back, midline, with needle angled in the posterior direction of the 
mouse.   The target area was prepared with an isopropyl swab.   A maximum of 
200 µL total suspension (1,000,000 to 4,000,000 cells) were injected via a 28ga 
needle after tenting the cutaneous layer.   The needle was allowed to remain in 
place for several seconds after injection to reduce inoculate backflow.  A sterile 
cotton swab was applied in the target area to reduce potential bleeding.   Flank 
inoculation with medulloblastoma cells is expected to produce palpable tumors 
within 6-8 days.  Tumor volume was assessed at least twice a week afterward.  
Tumor volume was not allowed to exceed 2.5cm^3 or 10% of subject body 
mass. Mice bearing flank tumors were observed daily for ulceration and necrosis.  
If noted, the mice were euthanized.    
Magnetic Resonance Imaging 
 Each mouse to be scanned was anesthetized by intraperitoneal 
administration of 100mg/kg Ketamine + 10mg/kg Xylazine (1 : 4).   Lubricating 
veterinary ointment was applied to the eyes and the animal was placed under a 
heating source.    Gd-DTPa was injected I.V. via tail vein for MRI to monitor 
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tumor growth.   Each mouse was placed in an acrylic imaging tube, secured via 
plastic ear bars, and fitted with a surface coil.  Images were acquired with a 2.4 
T, 40-cm bore magnet (Bruker Medical, Inc., Billerica, MA) equipped with a 12 
cm inner-diameter, actively shielded gradient insert  (maximum gradient 
strength: 25 G/cm).   An actively decoupled RF coil set was used for RF 
excitation/reception and was comprised of a 7 cm inner-diameter “birdcage” 
design resonator and a 2 cm diameter circular surface coil.    
T1 images 
 A two-dimensional T1 imaging series was generated with a spin echo, 
echo-planar imaging sequence preceded by an inversion recovery preparation 
period using a hyperbolic secant inversion pulse.  Data was obtained on 3 
coronal sections are 20 mm square and at a thickness of 2.5 mm.  Inversion 
recovery times were: 30, 60, 150, 300, 700, 1300, and 2500 msec. 
Derivation of Human Derived Tumor Cells 
 Human Medulloblastoma xenograft derived from a tumor of a 4-year old 
male patient.   Established under approved research protocols, and characterized 
in our laboratory  (Pediatric Neuro-Oncology Laboratory, Virginia Commonwealth 
University).  Samples of tumor were first obtained to allow full neuropathologic 
evaluation and diagnosis, as required for clinical management of the patient’s 
disease.  The site of origin of all tumor samples was cerebellum.  Cells were 
grown in DMEM supplemented with 10% heat-inactivated fetal bovine serum, 
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glutamine, and 1% penicillin-streptomycin solution at 37*C temperature with 5% 
CO2 in a humidified incubator.   All tissue culture reagents and supplements 
were obtained from Gibco BRL (Grand Island, NY) unless otherwise noted.   
Monolayers of tumor cells were typsinized, counted on a hemacytometer and 
viability was assessed by trypan blue exclusion.   Cells were washed twice in 
phosphate buffered saline (PBS) and concentration was adjusted appropriately 
(Graf et al. 2005). 
Determination of Tumor Volume from MRI 
 The three-dimensional volume of a tumor determined from a two-
dimensional MRI scan uses the equation for the volume of a spheroid.  In this 
equation, the volume is equal to four times the radius cubed, all divided by 
three.  Replacing the radius with the diameter divided by two, and making the 
diameter cubed equal to the width of the tumor times the height of the tumor 
times the width of the MRI slice, gives a simplified equation for volume.  The 
volume of a spheroid can be estimated as the width of the tumor times the 
height of the tumor times the slice width, all divided by two (!/6 being 
approximately !).   
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Quantification of VC312 mRNA levels  
 Total RNA was isolated from VC312 tumor tissue using TRIzol reagent, 
using the manufacturer’s protocol (Invitrogen, CA) and standard extraction 
protocol (Sambrook and Russell, 2001).  To prepare tissue extracts for RNA 
isolation, flash frozen pieces were ground to a fine powder with a frozen mortar 
and pestle prior to being added to TRIzol reagent. RNA was quantified using 
spectrophotometry to assess concentration of the RNA in the extracts and 
treated with RQ1 DNase (Promega, Madison, WI) using the manufacturer’s 
protocol.   
Western blot analysis for phosphorylated and total AKT 
 Cultured adherent cells in T-75 flasks were washed with PBS and 
incubated with 1 ml of ice-cold RIPA lysis buffer (50 mM Tris-HCl, 150 NaCl, 
0.5% SDS, 1% sodium deoxycholate, 1% Nonidet p-40) for 5 minutes on ice 
with gentle agitation.  Cells were scraped from flasks, sheared with 26.5 gauge 
needle and centrifuged at 16000 rpm for 30 minutes at 4°C.   Supernatant was 
collected and stored at -80°C until use.  Alternatively, frozen tumor tissue 
samples from primary medulloblastoma samples were thawed and suspended in 
800 !L ice-cold RIPA buffer containing protease inhibitor cocktail (Calbiochem, 
San Diego, CA) and mechanically homogenized.  The homogenized tissue was 
incubated at 4°C for 15 minutes and centrifuged at 16000 rpm for 30 minutes at 
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4°C.   Protein supernatants were aliquoted and stored at -80°C until use.  
Proteins were quantified using the Lowry method and BioRad DC reagent 
(BioRad, Hercules, CA) using the manufacturer’s protocol.  A BSA (Pierce, 
Rockland, IL) standard curve was used (25!g/ml to 2000!g/ml range).   Equal 
amounts of protein were loaded onto Bis-Tris 4-12% density gradient gels 
(Invitrogen, Carlsbad, CA) for SDS-PAGE at 120 V using the manufacturer’s 
power source and protocol (Novex).   Proteins were transferred (1 hour at 30V) 
onto nitrocellulose (Invitrogen) and incubated with 15 ml blocking buffer [5% 
bovine milk in Tris-buffered saline (50 mM Tris, pH 7.6, 150 NaCl) plus 0.05% 
Tween-20] for 1 hour at room temperature with gentle agitation.  Primary 
antibody [anti-Phospho-AKT (1:2000), Pan-AKT (1:2000) and anti-beta-actin 
(1:2000)] were added to 10 ml blocking buffer and incubated overnight at 4°C 
with gentle agitation.  Membranes were washed with rinse buffer [Tris buffered 
saline (50 mM Tris, pH 7.6, 150 NaCl) plus 0.05% Tween-20] for 6 x 5 minutes 
with vigorous agitation.   HRR-conjugated secondary antibody was added to 10 
ml blocking buffer (1:3000, ) and incubated for 1 hour at room temperature with 
gentle agitation.   Membranes were washed as before and developed using 
enhanced chemiluminescence (ECL) reagents (Amersham Biosciences, 
Piscataway, NJ) and the manufacturer’s protocol.   Immunoreactivity was 
visualized by exposure to autoradiography film (Marsh) and was developed using 
an X-OMAT developer (Kodak, Rochester, NY).  For quantitative analysis, optical 
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densities of autoradiographic bands were measured using ImageQuantTM 
software (Amersham Biosciences, Piscataway, NJ).   
Determination of Tumor Volume from Caliper measurements 
 The volume of subcutaneous tumor volumes is an important tool in 
assessing disease growth and effectiveness of therapeutics.  Manual calipers are 
used as a noninvasive technique for measuring tumor volume.   The 2 longest 
perpendicular axes of each xenograft tumor were measured to the nearest 0.1 
mm by an investigator familiar with collecting caliper measurements of xenograft 
tumors in mice. The depth was assumed to be equivalent to the shortest of the 
perpendicular axes, defined as y (Tomayko et al, 1989; Euhus et al, 1986).  
 Xenograft Tumor Volume = xy2 / 2. 
In Vivo Analysis of Effects of Perifosine on VC312 Tumor Growth 
 Groups of mice were inoculated with VC312 tumor cells as described 
previously.  When the mice reached post-inoculation day 15 with measurable 
tumors, perifosine-containing (36 mg/kg/d) or placebo drinking water was 
refreshed every 48 hours for up to 20 days by (n = 4 mice per group).  An 
amount of 15 mg of Perifosine was weighed and dissolved in 100 mL of sterile 
water.  Average daily water consumption was 5 ml per day, resulting in an 
average daily dose of 36 mg/kg/d or 252 mg/kg/wk.   The dimensions of the 
resulting tumors were determined at least three times per week using a digital 
caliper, and the tumor volume (cubic millimeter) was calculated as described 
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above.  The mice were sacrificed by asphyxiation with regulated CO2, and the 
tumors were excised, snap frozen in liquid nitrogen then transferred to a freezer 
at –80°C, until use. Protein extracts from the tumors were used to assess the 
phosphorylation status of AKT. To determine the effect of perifosine on survival, 
we counted the days from the date the treatment (perifosine or control) was 
begun to the time the control cohort of mice were sacrificed or to the end of the 
perifosine treatment or until euthanasia, as described previously (Zhijie et al, 
2010).  
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Chapter 4 
 
Results 
 
 
Creation of Intracerebellar Medulloblastoma Murine Model 
 
 The Medulloblastoma cell line VC312 was derived from a tumor of a 4-
year-old male patient. The primary culture (VC312) of MB was derived from a 
tumor of a 2-year old male patient treated at the Virginia Commonwealth 
University Health System’s Medical College of Virginia Hospital under an IRB 
approved protocol. Briefly, samples of the tumor were first obtained to allow full 
neuropathologic evaluation and diagnosis, as required for the clinical 
management of the patient’s disease. The sterile dissection of tumor biopsy was 
dissociated and plated in 6-well tissue culture plates and expanded in DMEM/F12 
medium supplemented with 1% N-2 supplement (Invitrogen), 5% FBS, 20 ng/ml 
recombinant human EGF and 10 ng/ml recombinant human bFGF (Beckton 
Dickenson). VC312 cells were subsequently maintained in DMEM (with L-
glutamine) supplemented with 10% FBS. 
 
Volume of Tumor Injection 
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 The proper volume of inoculum had to be determined in order to induce 
reliable tumor formation within a relatively brief time course, but without 
undesirable adverse effects on the recipient animals.  It was decided that roughly 
10% of the total cerebellar volume would be an acceptable maximum initial 
tumor cell infusion, so as to avoid adverse effects of the relatively rapid infusion 
process.  Thus, based upon the average athymic nude female mouse cerebellum 
volume being approximately 60 $L (Airey et al. 2001), we concluded that 6 $L 
would be the volume of the tumor inoculum.   The tumor cell concentration for 
the inoculum was determined from previous experiments performed in our lab as 
being a maximum concentration without blocking the fine needle of the Hamilton 
syringe (Nottingham 2008).  This concentration is equal to 50,000 cells per $L, 
which amounts to 300,000 VC312 cells per injection.    
Establishment of tumor inoculum into cerebellum 
 Our lab has completed orthotopic cancer experiments in the past but 
never in the cerebellum.   Therefore, proper stereotactic coordinates using the 
athymic mouse skull sutures had to be established.  Using the Mouse Brain Atlas 
(mbl.org)(Figure 4-1) it was determined that 1.5 mm posterior from Lambda, 
3.0mm lateral and 3.0 mm deep would place the inoculum in the right 
hemisphere of the posterior lobe of the cerebellum.  
The growth of VC312 xenograft tumor in the cerebellum was confirmed 
with MRI (Figure 4-2) and dissection of the mouse brain.  Once the growth of 
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the human tumor-derived cell line was confirmed, the development of an in vivo 
growth pattern for a primary medulloblastoma in the mouse cerebellum could 
begin.  
Hematoxylin and Eosin Staining 
 Hematoxylin and Eosin (H&E) stains were performed on representative 
formalin-fixed, paraffin embedded tissue sections from representative animals 
from all stereotactic infusion parameters by the VCU Anatomic Pathology 
Research Services.   
Tumor Bearing Mice 
 Consistent results were observed among all tumor-bearing mice, and as 
with the stereotactic infusions, the region of interest was the right cerebellum.   
 On MRI (Figure 4-2), Gd-enhanced T1-weighted imaging qualitatively 
showed tumor enhancement in the cerebellum and around the brain stem.    
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Figure 4-1.  Scaled Image from Mouse Brain Atlas.  Image illustrates the location 
of Lambda (lj) as the intersection of the sagittal and lambdoid sutures.  The burr 
hole was positioned: 1.5 mm anterior, 2.5 mm lateral to lambda, and the 
inoculum was positioned 3.0 mm ventral to the burr hole placement. placing the 
VC312 cells in the lateral portion of the cerebellum. 
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Figure 4-2. Gd-enhanced T1-weighted MRI of an animal on Day 17 Post 
Implantation. The image demonstrates a coronal slice from the mouse 
cerebellum.  The tumor boundary is visible as hyper-intensity seen in the lateral 
aspect of the cerebellum. 
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 The tumor growth in the intracerebellar model was measured using a 
formula for the volume of a spheroid (described in the Methods section) at 7 
days, 14 days, 21 days and 28 days post-implantation.   The average growth of 
the MB in the nude mouse cerebellum can be seen in Figure 4-3.    
 Consistent results were observed in the flank tumor bearing mice, the 
region of interest was the flank region and the subcutaneous growth of the 
tumor (Figure 4-4).  The dimensions of the tumors were measured using a 
caliper every third day.  
Histology of Tumor 
 The representative histological images of the in vivo tumors can be seen 
in figure 4-5.  The tumor is very cellular, with many mitoses and little 
cytoplasm.  The cells appear to form clusters and rosettes. 
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Figure 4-3. Volumetric Growth of Murine Intracerebellar MB. 
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Figure 4-4.  Image of a subcutaneous VC312 flank tumor.  
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Figure 4-5. Histology of Intracerebellar and Flank VC312 Tumors. 
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The Effect of Perifosine on Medulloblastoma cells in vitro 
  
Previous work by Dr. Anil Kumar in this laboratory studied the effect of the 
therapeutic agent Perifosone on different MB cell lines in vitro (Kumar et al., 
2009).   His data showed that endogenous active AKT is present at high levels 
compared with normal brain samples in MB and derivative cell lines.  Treatment 
of the MB with perifosine decreases the active AKT levels in a dose-dependent 
and time-dependent manner.  He also showed that perifosine treatment led to 
rapid decreases in cell survival in tumor cells.  Dr. Kumar also reported that 
exposure to etoposide and radiation followed with perifosine resulted in greater 
thant additive effect on cell death. These results indicate that perifosine, either 
alone or in combination with other drugs, might be an effective therapeutic 
agent for the treatment of MB.  These results highlight the potential value of 
studying of the effects of Perifosine in an in vivo model.  
The Effect of Perifosine on Medulloblastoma in vivo 
 Treatment of tumor bearing mice resulted in a decrease of overall tumor 
volume in both intracerebellar and flank models.  The intracerebellar-implanted 
mice were given perifosine treatment beginning sixteen days post-implantation.   
The volumetric growth of the intracerebellar implanted MB appears sporadic 
initially (Figure 4-6A).  However, the effect of perifosine begins to appear when 
the tumor volumes are separated into treated and untreated groups and their  
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volumes are averaged (Figure 4-6B).  Finally, when the tumor volumes are 
normalized to the size of the tumor upon initial inspection with MRI (day 7), the 
effect of perifosine within the treatment group was significant (figure 4-7).    
 The effect of perifosine on the growth of the flank tumor model is 
illustrated in Figure 4-8.  The tumor sizes were normalized to the size of the 
tumor at the beginning of treatment and averaged.  The effect of perifosine is 
significant from eight days post-treatment until the end of the study.    
 The intracerebellar-implanted mice were given perifosine treatment 
following the MRI at day 14.   At day 35 post implantation only the four mice 
treated with perifosine remained alive.  Using a Fisher’s exact test to evaluate 
the significance, the effect of perifosine on the survival of intracerebellar-
implanted mice is significant (Table 4-1).       
 The effect of perifosine on the signaling pathways of MB is illustrated in 
figure 4-9 by the suppression of active AKT in treated versus untreated MB flank 
tumors.   Qualitative effects of perifosine on the histology of the tumor are 
illustrated in the decreased density of stained cells.  Further, when the tumors 
were stained with Ki-67, a cellular marker for proliferation, the Ki-67 sections 
showed qualitative differences between the treated and untreated tumors.  The 
treated tumor sections displayed a lower density of Ki—67 positive cells than the 
untreated tumor sections.  Therefore, perifosine effectively suppressed the 
proliferation of MB cells in the treated animal model.  
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Figure 4-6. Effect of Perifosine on Growth of Murine Intracerebellar 
Medulloblastoma. A. The volumetric growth data for each intracerebellar-
implanted mouse are plotted individually. B. The average volumetric growth rates 
for perifosine-treated vs untreated mice are demonstrated. 
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Figure 4-7. The Effect of Perifosine on the growth of murine intracerebellar 
medulloblastoma.  Treatment with perifosine began on day 17 post-implantation.   
Tumor volumes have been normalized to the volume of the tumor at initial MRI 
inspection on day 7 post implantation. 
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Figure 4-8. Effect of Perifosine Treatment on Growth of Medulloblastoma Flank 
Tumors.  Tumor volumes have been normalized to the volume of the tumor at 
the beginning of treatment. 
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Table 4-1.  Effect of Perifosine on Survival of Mice with intracerebellar 
implantation of Medulloblastoma. 
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Figure 4-9. Suppression of active AKT by perifosine in VC312 flank tumors. Flank 
tumor-bearing mice were treated with perifosine for 20 days and the cell lysates 
were then subjected to Western blot analysis.  
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Figure 4-10. The effect of perifosine on the histology of medulloblastoma in a 
flank tumor model.  A. Hematoxylin and eosin staining of treated and untreated 
tumor sections.  B. Flank tumor sections stained for Ki-67, a marker for cellular 
proliferation. 
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Chapter  5 
Discussion 
  
 
The medulloblastoma is the most common malignant pediatric brain 
tumor, and is still associated with mortality and severe side effects from clinical 
treatment (Packer et al., 2003).  The development of a clinically relevant in vivo 
model is important not only to further understand the disease but also to provide 
a new and improved means with which to test novel therapeutics.   The standard 
in vitro experimental models of human cancer cell lines do not accurately 
replicate the conditions, three-dimensional interaction or microenvironment that 
a tumor experiences in vivo and orthotopically.    
Current models of replicating MB include genetically engineered animal 
models (Hatton et al., 2008) and orthotopic xenograft models (Kessler et al., 
2009).  These models fail to use a human tumor cell line, which reduces their 
usefulness for studying therapies designed for humans.  Further, the clinical 
effectiveness of novel therapeutic strategies can more accurately be predicted 
when human tumor-derived cell lines are used in an orthotopic xenograft model 
(Hoffman et al., 1999). 
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Previous intracerebellar xenograft models have been established in SCID 
mice, systematically developed and broadly characterized for multiple established 
MB cell lines (Qin et al., 2006) excluding VC312.  However, these models have 
the serious limitation of using established cell lines that have a homogeneous cell 
population, uniform growth rate and hypersensitivity to therapy (Qin et al., 
2008).  The development and volumetric characterization using MRI of an 
orthotopically implanted primary human MB tumor has not been reported.    
In this study, we described the establishment of an intracerebellar model 
in athymic nude mice with cells cultured from a primary human tumor.   Utilizing 
MRI and a flank tumor model to establish the volumetric growth of the tumor in 
vivo we evaluated the preclinical effectiveness of the anti-AKT activities of 
perifosine, an established anti-cancer drug that has been taken to phase II 
clinical trials for peripheral cancers (Gills and Dennis, 2009).   Our lab had 
previously studied the in vitro effects of perifosine and showed that it possessed 
potent suppression of AKT signaling activity by decreasing cancer cell survival 
and growth (Kumar, et al., 2009). The literature documents that the 
phosphatidylinositol 3!-kinase (PI3K)–mediated AKT signaling pathway has been 
found to have a role in tumor proliferation and survival (Vivanco et al., 2002), 
making the AKT signaling pathway a valuable target for anti-tumor therapeutics.  
Further, elevated activation of PI3K/AKT signaling pathways has been found in 
MB (Hartmann et al., 2006).   
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Repeated MRI scans illustrated volumetric growth and histopathological 
features similar to the primary tumor which confirmed successful establishment 
of an intracerebellar MB model in nude mice.  Using this model, we showed the 
effect of perifosine on suppressing tumor growth both in the orthotopic 
intracerebellar model and in the flank model.  Perifosine also effectively 
increased survival of mice bearing intracerebellar tumors.   Further, perifosine 
effectively suppressed active AKT signaling and reduced the density of 
proliferating cells in vivo. 
An advantage of xenograft models is that the relative tumor growth 
dynamics can roughly be predicted by the concentration of tumor cells implanted 
(Lampson et al., 2001).  Therefore, identical cell concentrations implanted in the 
same stereotactic position in the cerebellum would theoretically grow at the 
same rate. A further advantage of such a xenograft model would be to allow 
objective measurement of the effectiveness of chemotherapy or other 
therapeutic strategies.  Unfortunately, we found there to be a large variation in 
the volumetric growth rates at days 14 and 21 post implantation.   However, by 
the end of the study, the sizes of the tumors measured from the MRI scans were 
approximately similar, while the overall rates of growth of individual tumors 
showed variability. 
While faithful reproduction of intracerebellar MB tumors was not 
confirmed with histology, leptomeningeal dissemination was evident in both the 
MRI scans and the prepared histology.   It should be noted that this corresponds 
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to a troubling clinical characteristic of MB in humans, with dissemination early in 
its course.  The murine model of intracerebellar MB established in this study thus 
appears to replicate dissemination in the CNS, especially around the brainstem. 
This may be a valuable model for novel therapeutic strategies targeting 
leptomeningeal dissemination of MB.   It is notable in this regard that despite 
prominent leptomeningeal dissemination in these animals, the group receiving 
perifosine had a significantly longer survival.  This provides significant hope that 
this therapeutic strategy could be effective against MB even in patients who have 
developed leptomeningeal spread of their tumor. 
Limitations of our model included the culturing of the primary tumor prior 
to implantation.  While the cell cultures of the MB used in the study were limited 
to less than five passages, the in vitro culturing could have had an effect on the 
heterogeneity of the cell population.   The homogeneous cell population would 
make for uniform growth and the possibility of sensitivity to therapy (Kamb et 
al., 2005).   A solution to this problem would be the implantation of freshly 
resected tumor pieces intracerebellarly, however due to the availability of the 
resected samples, cultured primary tumor cells were the best option.  Another 
issue that should be addressed is the location of the tumor implantation.   The 
majority of MBs grow from the vermis of the cerebellum, the site of massive 
cellular differentiation during development.   The implantation was positioned in 
the right hemisphere of the lateral lobe of the cerebellum because it was the 
only feasible target in the cerebellum.  Due to the size of the cerebellum in these 
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animals, it was far too difficult to position the implantation in the vermis.  
Further, the mice used in the study were young adults (4-6 weeks) whose 
cerebellar development was mostly complete, potentially reducing the 
microenvironment difference between vermis and lateral hemisphere.   
Future studies with this model approach would be appropriate to address 
a number of issues highlighted by this work, to improve and extend the 
important findings here.  In particular the stereotactic refinement, tumor 
reproducibility and perifosine dose optimization.  Refining the stereotactic 
coordinates would improve the reproducibility of the model in the cerebellum. 
Proper tumor implantation is the keystone of this model, continuing to optimize 
the surgical protocol will allow extension of this model to explore signaling, 
angiogenesis and dissemination of the disease.  Further, faithful orthotopic 
implantation and growth of the primary human MB in the cerebellum allows the 
further characterizing of the complexities of this tumor; it will also permit 
refinement of the perifosine growth suppression mechanism in vivo.  
In order to improve reproducibility; the size and age of mice used in the 
model need to be standardized.  The volume of the cerebellum varies with each 
subject and therefore proper implantation location can fluctuate.  Correlating the 
stereotactic coordinates to the size and age of the animal should improve the 
accuracy of the implantation and the model’s orthotopic fidelity.   
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Maximum anti-tumor effect while maintaining increased survival benefits is 
the goal of perifosine dose optimization.   Exploring the time dependence of 
perifosine effectiveness is a logical extension of the therapeutic enhancement. 
Further, characterizing the suppression of subarachnoid growth will improve the 
understanding of the survival benefits of perifosine. 
Finally, optimization of the intracerebellar MB model will allow utilization of the 
approaches learned in this work to be applied to newly obtained primary tumor 
samples of MB.       
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